Eckert & Ziegler stock posts 25% adjusted EBIT growth in Q3
Published on 11/12/2026 at 17:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSProfit growth supports confirmed guidance
- Third-quarter adjusted EBIT rose to 19.3 million euros from 15.4 million euros a year earlier.
- Nine-month net income increased 19 percent despite a missing prior-year license contribution.
- Management expects fourth-quarter license revenue and maintained its 2026 targets.
Eckert & Ziegler reported stronger third-quarter profitability on Thursday, November 12, with adjusted EBIT rising to 19.3 million euros from 15.4 million euros a year earlier. The medical isotope specialist also confirmed its full-year targets, giving investors a fresh measure of the operating recovery.
The figures were published in Eckert & Ziegler's corporate release. Third-quarter sales increased to 79.6 million euros from 75.3 million euros, while net income climbed to 13.1 million euros from 8.5 million euros.
Operating momentum improves
For the first nine months, sales reached 229.0 million euros, compared with 224.1 million euros in the prior-year period. Adjusted EBIT rose to 52.6 million euros from 50.8 million euros, and net income advanced to 35.4 million euros.
The comparison benefits from a significant base effect. The prior-year period included 5.0 million euros of license revenue, while the company expects license income in the fourth quarter of 2026. Excluding that effect, nine-month sales growth was 4 percent and adjusted EBIT growth was 14 percent, according to the release.
Medical segment adjusted EBIT increased 16 percent to 36.2 million euros. In Isotope Products, adjusted EBIT for the first nine months fell 11 percent to 17.9 million euros, but third-quarter adjusted EBIT improved to 8.6 million euros from 7.8 million euros and gross margin expanded to 47 percent from 45 percent.
Guidance remains unchanged
Management continues to expect 2026 sales of around 320 million euros and adjusted EBIT of around 80 million euros. The company cited expected license revenue and continued demand for radiopharmaceutical products as support for reaching those targets.
Eckert & Ziegler stock traded at 14.50 euros on Lang & Schwarz at 17:39 CET on Thursday, November 12, 2026, 0.62 percent above the Xetra close of Thursday, November 12.
Eckert & Ziegler SE
- Company: Eckert & Ziegler SE
- ISIN: DE0005659700
- Ticker: EUZ.DE
- Primary exchange: Xetra
- Lang & Schwarz price: 14.50 euros on Thursday, November 12, 2026, at 17:39 CET
- Xetra close: 14.41 euros on Thursday, November 12, 2026
- 2026 sales target: Around 320 million euros
- 2026 adjusted EBIT target: Around 80 million euros
German equities provide the broader market backdrop through the DAX market overview.
